XORTX Therapeutics Inc (XRTX)
2.575
+0.06
(+2.24%)
USD |
NASDAQ |
May 31, 16:00
2.42
-0.16
(-6.02%)
After-Hours: 20:00
XORTX Therapeutics Enterprise Value: 3.641M for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 3.641M |
| May 30, 2024 | 3.478M |
| May 29, 2024 | 3.424M |
| May 28, 2024 | 3.685M |
| May 24, 2024 | 3.656M |
| May 23, 2024 | 3.714M |
| May 22, 2024 | 3.743M |
| May 21, 2024 | 3.772M |
| May 20, 2024 | 3.325M |
| May 17, 2024 | 3.423M |
| May 16, 2024 | 2.988M |
| May 15, 2024 | 3.394M |
| May 14, 2024 | 3.278M |
| May 13, 2024 | 3.453M |
| May 10, 2024 | 3.482M |
| May 09, 2024 | 3.946M |
| May 08, 2024 | 4.033M |
| May 07, 2024 | 3.888M |
| May 06, 2024 | 3.859M |
| May 03, 2024 | 3.938M |
| May 02, 2024 | 3.710M |
| May 01, 2024 | 3.602M |
| April 30, 2024 | 3.569M |
| April 29, 2024 | 3.845M |
| April 26, 2024 | 4.672M |
| Date | Value |
|---|---|
| April 25, 2024 | 3.685M |
| April 24, 2024 | 4.590M |
| April 23, 2024 | 4.701M |
| April 22, 2024 | 4.875M |
| April 19, 2024 | 4.867M |
| April 18, 2024 | 5.021M |
| April 17, 2024 | 5.369M |
| April 16, 2024 | 5.166M |
| April 15, 2024 | 5.514M |
| April 12, 2024 | 5.921M |
| April 11, 2024 | 6.487M |
| April 10, 2024 | 6.366M |
| April 09, 2024 | 7.227M |
| April 08, 2024 | 7.502M |
| April 05, 2024 | 6.908M |
| April 04, 2024 | 6.414M |
| April 03, 2024 | 5.601M |
| April 02, 2024 | 5.964M |
| April 01, 2024 | 6.734M |
| March 28, 2024 | 7.277M |
| March 27, 2024 | 6.987M |
| March 26, 2024 | 7.567M |
| March 25, 2024 | 7.640M |
| March 22, 2024 | 9.451M |
| March 21, 2024 | 10.57M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-2.337M
Minimum
Mar 28 2023
63.05M
Maximum
Sep 07 2021
9.322M
Average
7.024M
Median
Apr 17 2020
Enterprise Value Benchmarks
| ImmunoPrecise Antibodies Ltd | 24.57M |
| Acasti Pharma Inc | 0.5379M |
| Aurinia Pharmaceuticals Inc | 424.68M |
| Edesa Biotech Inc | 11.48M |
| Lexaria Bioscience Corp | 45.09M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -3.019M |
| Total Expenses (Quarterly) | 1.089M |
| EPS Diluted (Quarterly) | -1.24 |
| Earnings Yield | -52.82% |